机构:[1]State Key Laboratory of Organ Failure Research, National Clinical Research Center for Kidney Disease, Guangzhou, China[2]Nanfang Hospital, SouthernMedical University, Guangzhou, China[3]Kingmed Center for Clinical Laboratory, Guangzhou, China[4]The First People’s Hospital of Foshan, Foshan, China[5]The People’s Hospital of Honghu, Honghu, China[6]The First People’s Hospital of Jingzhou, Jingzhou, China[7]Jingzhou Central Hospital, Jingzhou, China[8]Honghu Traditional Chinese Medicine Hospital, Honghu, China[9]The Second People’s Hospital of Honghu, Honghu, China[10]Department of AppliedBiology and Chemical Technology, Hong Kong Polytechnic University, Hung Hom, Hong Kong, China[11]Department of Computer Science and Technology,Tsinghua University, Beijing, China[12]The Sichuan Provincial Key Laboratory of Human Disease Study, Institute of Laboratory Medicine, Sichuan ProvincialPeople’s Hospital, University of Electronic Science and Technology of China, Chengdu, China四川省人民医院[13]Key Laboratory of Molecular Biology on Infectious Diseases,Ministry of Education, Chongqing Medical University, Chongqing, China[14]Center for Biomedicine and Innovations, Faculty of Medicine, Macau Universityof Science and Technology, Macau, China[15]Guangzhou Regenerative Medicine and Health Guangdong Laboratory, Guangzhou, China
Detection of asymptomatic or subclinical novel human coronavirus SARS-CoV-2 infection is critical for understanding the overall prevalence and infection potential of COVID-19. To estimate the cumulative prevalence of SARS-CoV-2 infection in China, we evaluated the host serologic response, measured by the levels of immunoglobulins M and G in 17,368 individuals, in the city of Wuhan, the epicenter of the COVID-19 pandemic in China, and geographic regions in the country, during the period from 9 March 2020 to 10 April 2020. In our cohorts, the seropositivity in Wuhan varied between 3.2% and 3.8% in different subcohorts. Seroposivity progressively decreased in other cities as the distance to the epicenter increased. Patients who visited a hospital for maintenance hemodialysis and healthcare workers also had a higher seroprevalence of 3.3% (51 of 1,542, 2.5-4.3%, 95% confidence interval (CI)) and 1.8% (81 of 4,384, 1.5-2.3%, 95% CI), respectively. More studies are needed to determine whether these results are generalizable to other populations and geographic locations, as well as to determine at what rate seroprevalence is increasing with the progress of the COVID-19 pandemic. Serologic surveillance has the potential to provide a more faithful cumulative viral attack rate for the first season of this novel SARS-CoV-2 infection. Initial results of serological surveillance in China provide valuable data for estimation of the cumulative prevalence of SARS-CoV-2 infection in the general population.
基金:
Clinical Innovation Research Program of Guangzhou Regenerative Medicine and Health Guangdong Laboratory [2018GZR0201003, 2018GZR110102004, 2020GZR110306001]; National Innovation Team Program [81521003]; Major Scientific and Technological Planning Project of Guangzhou [201607020004]; Macao FDCT [0035/2020/A]
语种:
外文
高被引:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2019]版:
大类|1 区医学
小类|1 区生化与分子生物学1 区细胞生物学1 区医学:研究与实验
最新[2025]版:
大类|1 区医学
小类|1 区生化与分子生物学1 区细胞生物学1 区医学:研究与实验
JCR分区:
出版当年[2018]版:
Q1MEDICINE, RESEARCH & EXPERIMENTALQ1CELL BIOLOGYQ1BIOCHEMISTRY & MOLECULAR BIOLOGY
最新[2024]版:
Q1BIOCHEMISTRY & MOLECULAR BIOLOGYQ1CELL BIOLOGYQ1MEDICINE, RESEARCH & EXPERIMENTAL
第一作者机构:[1]State Key Laboratory of Organ Failure Research, National Clinical Research Center for Kidney Disease, Guangzhou, China[2]Nanfang Hospital, SouthernMedical University, Guangzhou, China
共同第一作者:
通讯作者:
通讯机构:[1]State Key Laboratory of Organ Failure Research, National Clinical Research Center for Kidney Disease, Guangzhou, China[2]Nanfang Hospital, SouthernMedical University, Guangzhou, China[14]Center for Biomedicine and Innovations, Faculty of Medicine, Macau Universityof Science and Technology, Macau, China[15]Guangzhou Regenerative Medicine and Health Guangdong Laboratory, Guangzhou, China
推荐引用方式(GB/T 7714):
Xin Xu,Jian Sun,Sheng Nie,et al.Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China[J].NATURE MEDICINE.2020,26(8):1193-+.doi:10.1038/s41591-020-0949-6.
APA:
Xin Xu,Jian Sun,Sheng Nie,Huiyuan Li,Yaozhong Kong...&Fan Fan Hou.(2020).Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China.NATURE MEDICINE,26,(8)
MLA:
Xin Xu,et al."Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China".NATURE MEDICINE 26..8(2020):1193-+